In a major achievement to Council of Scientific & Industrial Research (CSIR), a research arm of Ministry of Science and Technology, the first ayurvedic anti-diabetic drug BGR-34 has passed the human trial test. The BGR-34 has become the first ayurvedic drug to get registered in the Clinical Trial Registry-India (CTRI), which has only over 2,000 allopathic registered medicines. The drug has been found useful in controlling sugar level and increasing insulin emissions in blood.
Talking to Millennium Post, AK Rawat, principal scientist at CSIR-NBRI, Lucknow, said, "As per the existing practice, it's must to put the clinical trial report of every manufactured drug at the CTRI for public review. Prior to BGR-34 registration with CTRI, the registration process was only for allopathic medicines. The clinical trial results of ayurvedic medicines would help in instilling confidence among patients about the natural drug, which is being manufactured by Aimil Pharmaceuticals."
Rawat further added that though it's not mandatory to put trial's data in public domain for ayurvedic medicines, but sharing the results will help patients and critics to understand about the efficacy of ayurvedic medicines.
The drug has been tested on animals as well as on humans. It has been tested on 64 patients of different groups ranging from 25 years to 60 years for over 4 months. According to the findings of the trial committee, the primary outcome of BGR-34 showed very promising results with respect to glycemic parameters in patients with type 2 diabetes mellitus.